2022
The therapeutic potential of psychedelics
Schindler E, D'Souza D. The therapeutic potential of psychedelics. Science 2022, 378: 1051-1053. PMID: 36480624, DOI: 10.1126/science.abn5486.Peer-Reviewed Original Research
2019
Medical Marijuana: What Physicians Need to Know.
Radhakrishnan R, Ranganathan M, D'Souza DC. Medical Marijuana: What Physicians Need to Know. The Journal Of Clinical Psychiatry 2019, 80 PMID: 31087827, DOI: 10.4088/jcp.18ac12537.Peer-Reviewed Original Research
2016
A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications.
Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. The Journal Of Clinical Psychiatry 2016, 77: 1050-64. PMID: 27561138, DOI: 10.4088/jcp.15r10036.BooksConceptsEfficacy of marijuanaPosttraumatic stress disorderPsychiatric indicationsStrength of evidenceTourette's disorderPsychiatric conditionsSystematic reviewAlzheimer's diseaseChronic cannabinoid exposureEfficacy of cannabinoidsUse of cannabinoidsAbsence of RCTsMedical marijuanaEmergence of psychosisLow-quality studiesBest available evidenceSafety of marijuanaPersistent marijuana useCannabinoid exposureClinical trialsPRISMA guidelinesSide effectsSpecific diagnosisGRADE methodsConstituent cannabinoids
2007
Psychiatric safety of ketamine in psychopharmacology research
Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O’Donnell E, Krystal JH, D’Souza D. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192: 253-260. PMID: 17458544, DOI: 10.1007/s00213-007-0706-2.Peer-Reviewed Original ResearchConceptsSubanesthetic dosesHealthy human subjectsKetamine administrationClinical research programHuman subjectsTest sessionsPsychotic spectrum disordersPsychiatric safetyResidual sequelaePlacebo infusionIntravenous infusionKetamine effectsPsychopharmacology studiesResultsFour hundredAdverse reactionsObjectiveTo reportHealthy subjectsStudy participationClinical investigationHealthy humansSide effectsKetamineInfusionDosesAdministration
1999
Symptom provocation studies in psychiatric disorders: scientific value, risks, and future
D’Souza D, Berman R, Krystal J, Charney D. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biological Psychiatry 1999, 46: 1060-1080. PMID: 10536743, DOI: 10.1016/s0006-3223(99)00209-7.Peer-Reviewed Original ResearchNMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) subclassChronic pain syndromePain syndromeGlutamatergic dysfunctionNMDA agonistClinical studiesMajor depressionNMDA antagonistsGlutamate receptorsCoagonist siteParkinson's diseaseHuman psychopharmacological studiesPartial agonistAlzheimer's diseaseNeuropsychiatric conditionsNeuropsychiatric disordersDiseasePsychopharmacological studiesAnxiety disordersHuntington's diseaseAgonistsAntagonistTherapeutic hypothesesDisordersAddiction disorders